JP5667885B2 - 化学的保護方法及び組成物 - Google Patents

化学的保護方法及び組成物 Download PDF

Info

Publication number
JP5667885B2
JP5667885B2 JP2010550648A JP2010550648A JP5667885B2 JP 5667885 B2 JP5667885 B2 JP 5667885B2 JP 2010550648 A JP2010550648 A JP 2010550648A JP 2010550648 A JP2010550648 A JP 2010550648A JP 5667885 B2 JP5667885 B2 JP 5667885B2
Authority
JP
Japan
Prior art keywords
dithio
bis
administration
paclitaxel
cisplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010550648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011514356A5 (enExample
JP2011514356A (ja
Inventor
ハウシェール，フレデリック，エイチ．
Original Assignee
バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド filed Critical バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド
Publication of JP2011514356A publication Critical patent/JP2011514356A/ja
Publication of JP2011514356A5 publication Critical patent/JP2011514356A5/ja
Application granted granted Critical
Publication of JP5667885B2 publication Critical patent/JP5667885B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010550648A 2008-03-14 2008-03-14 化学的保護方法及び組成物 Active JP5667885B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/003406 WO2009113984A1 (en) 2008-03-14 2008-03-14 Chemoprotective methods and compositions

Publications (3)

Publication Number Publication Date
JP2011514356A JP2011514356A (ja) 2011-05-06
JP2011514356A5 JP2011514356A5 (enExample) 2011-06-16
JP5667885B2 true JP5667885B2 (ja) 2015-02-12

Family

ID=41065493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550648A Active JP5667885B2 (ja) 2008-03-14 2008-03-14 化学的保護方法及び組成物

Country Status (6)

Country Link
EP (1) EP2252246B1 (enExample)
JP (1) JP5667885B2 (enExample)
AU (1) AU2008352598B2 (enExample)
CA (1) CA2717915A1 (enExample)
ES (1) ES2476602T3 (enExample)
WO (1) WO2009113984A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176437A1 (en) * 2015-04-28 2016-11-03 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
KR20200028950A (ko) * 2017-06-14 2020-03-17 에이디씨 테라퓨틱스 에스에이 항-cd25 adc의 투여를 위한 투약량 체제
KR20210062029A (ko) * 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
SG11202109705YA (en) * 2019-03-08 2021-10-28 Lantern Pharma Inc Method for treating female non-smokers with non-small cell lung cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7021A (en) * 1850-01-15 Substitute for the clevis
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US6037336A (en) 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
JP2004523518A (ja) * 2001-01-19 2004-08-05 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド より効能が大きく副作用の少ない癌治療方法
US7176192B2 (en) * 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
WO2005051444A2 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
US20050256055A1 (en) * 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
AU2006326442B2 (en) * 2005-12-13 2012-03-01 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions

Also Published As

Publication number Publication date
EP2252246B1 (en) 2014-06-18
EP2252246A4 (en) 2011-10-26
EP2252246A1 (en) 2010-11-24
AU2008352598A1 (en) 2009-09-17
ES2476602T3 (es) 2014-07-15
AU2008352598B2 (en) 2012-06-07
CA2717915A1 (en) 2009-09-17
WO2009113984A1 (en) 2009-09-17
JP2011514356A (ja) 2011-05-06

Similar Documents

Publication Publication Date Title
US8143236B2 (en) Chemoprotective methods
Argyriou et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer
Kohler et al. Paclitaxel (taxol)
RU2576609C2 (ru) Способы лечение рака поджелудочной железы
Sessa et al. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule
CA2960611A1 (en) Neuroactive steroids, compositions, and uses thereof
KR20110128339A (ko) 티오콜키신 유도체와의 조합 요법
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
US8026227B2 (en) Chemoprotective methods and compositions
TW200803842A (en) Antineoplastic combinations of temsirolimus and sunitinib malate
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
JP5667885B2 (ja) 化学的保護方法及び組成物
KR20200118823A (ko) 펜타아자 마크로시클릭 고리 복합체 및 백금-기재 항암제를 사용한 조합 암 요법
Merheb et al. Drug-induced peripheral neuropathy: diagnosis and management
SK287762B6 (sk) Použitie aplidínu na prípravu farmaceutického prostriedku na liečenie rakoviny
US10786505B2 (en) Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents
Hausheer Chemotherapy-induced peripheral neuropathy
JP2008169220A (ja) 癌を処置または予防するためのβ−ラパコンの使用
KR20180006417A (ko) 카바지탁셀 및 암 치료에 대한 그의 용도
JP2019131508A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
JPWO2012137645A1 (ja) 抗癌剤に起因する異痛症の予防及び／又は治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140918

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141215

R150 Certificate of patent or registration of utility model

Ref document number: 5667885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250